​​​ On risk-based inspections, it said that while implementing the Schedule-M, "no risk-based inspection should be undertaken, except on critical issues, till December 2026, and thereafter in case of further extension," the letter said. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/msme-pharma-body-calls-for-waiver-of-risk-based-inspections-amid-upgrade/121372251